MedTrace Logo

Validation of the Stockholm3 Test for Detection of Prostate Cancer in the Swiss Population

NCT05294627 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 380

Last updated 2023-12-12

No results posted yet for this study

Summary

The purpose of this study is to collect blood samples to investigate the prognostic performance of the STHLM3 test in a population of Swiss and German men suspected of harbouring prostate cancer based on a combination of elevated PSA levels (e.g. \>2.5 ng/ml) and/or pathological digital rectal examination and/or MRI-findings.

Conditions

Interventions

DIAGNOSTIC_TEST

Stockholm3

Stockholm3 test prior to prostate biopsy. Prostate biopsy is preformed irrespective of the Stockholm3 score.

Sponsors & Collaborators

  • Department of Urology, University Hospital Freiburg, Freiburg, Germany

    collaborator UNKNOWN

  • Department of Urology, Kantonsspital Graubünden, Chur, Switzerland

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Ashkan Mortezavi · Universitätsspital Basel

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-11-01
Completion
2023-10-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05294627 on ClinicalTrials.gov